All In Biotech

Drug Trial Radar · NCT04061421

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Nov 24, 2021

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Michael SavonaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Incyte Corporation; Theradex; Astex Pharmaceuticals, Inc.
First posted
Aug 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.

Conditions

  • MDS/MPN

Interventions

  • ASTX727Drug

    Taken by mouth daily during days 1-5 of every 28-day cycle.

  • ItacitinibDrug

    Taken by mouth daily during each 28-day cycle

  • RuxolitinibDrug

    Dosage will be 5,15, or 20mg Taken by mouth BID for 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Determination of doseTime frame: Up to 28 days
  2. Phase 2: Overall response rate (ORR). Overall response includes patients who achieve best response of CR, PR, MR, or CB as defined by the MDS/MPN IWG proposed response criteriaTime frame: Up to 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Rochester Wilmot Cancer Institute

    Rochester, New York · Recruiting

  • Oregon Health Sciences University

    Portland, Oregon · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.